CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Natural killer cells in antitumour adoptive cell immunotherapy
TJ Laskowski, A Biederstädt, K Rezvani - Nature Reviews Cancer, 2022 - nature.com
Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
CAR T cells in solid tumors: challenges and opportunities
F Marofi, R Motavalli, VA Safonov… - Stem cell research & …, 2021 - Springer
Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2021 - nature.com
Chimeric antigen receptors (CARs) are engineered proteins designed to target T cells to
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
P Agarwalla, EA Ogunnaike, S Ahn, KA Froehlich… - Nature …, 2022 - nature.com
Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …
malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing …
Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
JN Brudno, JN Kochenderfer - Blood reviews, 2019 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
Cytokine release syndrome
A Shimabukuro-Vornhagen, P Gödel… - … for immunotherapy of …, 2018 - Springer
During the last decade the field of cancer immunotherapy has witnessed impressive
progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T …
progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T …
[HTML][HTML] A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy
Chimeric antigen receptor (CAR)-T cell-based immunotherapy for cancer and
immunological diseases has made great strides, but it still faces multiple hurdles. Finding …
immunological diseases has made great strides, but it still faces multiple hurdles. Finding …